33 results about "Spasticity" patented technology

Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

The invention is directed to topical formulations and methods of treating a migraines and / or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof.

There is provided a system and a method for quantitative measurement of spasticity in a patient. It has been found that stretch reflex measurements, that are quantitatively indicative of spasticity, can be obtained by recording an EMG signal while the limb is being moved at a variety of angular velocities. The method advantageously allows the clinician to perform the test at the bedside by eliminating the need for cumbersome mechanical components for moving the limb while providing quantitative measurements.

The present invention relates to piperazine phenothiazine derivatives useful as therapeutic agents for treating spasticity, particularly following an ischemia or traumatic injury, or compression syndrome. The invention further relates to a pharmaceutical composition comprising a compound of the invention for treating spasticity.

The invention discloses a spasm recovery device for hemiplegia patients, which relates to the technical field of medical devices and includes: a bed body including a bed board; The lower side of the baffle is provided with a baffle driving mechanism, which can drive the first baffle to move in the width direction of the bed; the shoulder lifting mechanism is movably arranged at the end of the bed near the head of the bed, and can drive the patient's shoulder on the affected side. The arm stretching mechanism is set above the bed board, which can drive the patient's wrist on the affected side to move to the shoulder on the other side; the device has a shoulder lifting mechanism, an arm stretching mechanism and a block that can squeeze the patient by moving. The board can easily help the patient relieve the spasticity of the trunk and arms by lifting the patient's shoulders and arms and repeatedly squeezing the patient's arms and trunk.

The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof: (I) wherein: n is 0 or 1; R1 is selected from H, alkyl and aralkyl, wherein said alkyl and aralkyl groups may be optionally substituted by one or more OH groups; X is a group selected from —C≡C—(CH2)p—; —C(R5)═C(R6)—(CH2)q—; and —C(R5)(R6)C(R7)(R8)—(CH2)r-; where each of R5, R6, R7 and R8 is independently H or alkyl, and each of p, q and r is independently 1, 2, 3, 4 or 5; Y is a group selected from: CN; COOR2; CONR3R4; SO2NR9R10; NR12COR13; NR14SO2R15; and a heterocyclic group selected from oxadiazolyl, thiazolyl, iso-thiazolyl, oxazolyl, iso-oxazolyl, pyrazolyl and imidazolyl; where each of R2, R3 and R4 is independently H or alkyl; or R3 and R4 are linked, together with the nitrogen to which they are attached, to form a 5 or 6-membered heterocycloalkyl or heterocycloalkenyl group, said heterocycloalkyl or heterocycloalkenyl group optionally containing one or more further groups selected from O, N, CO and S, and where each of R9, R10, R11, R12, R13, R14 and R15 is independently H or alkyl. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, pain, or for controlling spasticity or tremors, for example, spasticity in MS.

A high concentration baclofen solution is provided suitable for therapeutic use in a medical setting. A high concentration solution of baclofen in multivalent physiological ion solution such as artificial cerebrospinal fluid is provided with concentrations of baclofen of 10 mg / ml. Artificial cerebrospinal fluid is particularly advantageous as a baclofen solvent. A medical package is also provided for baclofen delivery to patients suffering from spasticity.

Described are methods, devices, and systems for a novel, easy to use treatment for spasticity that does not involve medication. Methods and devices herein use low-frequency repetitive magnetic fields to enhance communication in the spinal nerve, thereby allowing improved relaxation, control, and coordination in a muscle.